Delaware County mother thanks paramedics who saved her baby outside closed Crozer-Chester Medical Center
In an exclusive interview with CBS News Philadelphia, Shaniqua Whitaker, of Marcus Hook, said she was at work at the time and her 5-month-old daughter, Shyanne Glen, was with her aunt.
"They just called and said she wasn't breathing and my heart just dropped," Whitaker said.
The medical emergency happened last week as a news conference outside the hospital in Upland, hosted by Pennsylvania Governor Josh Shapiro, was wrapping up.
Dai'shanik Dickerson, Shyanne's aunt, said she was driving to Hobby Lobby with her niece in the back seat when she noticed something was wrong.
Dickerson pulled over next to a group of paramedics and police officers who were gathered for the news conference.
"When the officer took [Shyanne] from my hands, she was weak at the point, and he patted her aggressively twice in the back, and she let out the noise," Dickerson said. "And that was like a breath of fresh air for me."
Even though Shyanne was at Crozer, she couldn't be admitted for treatment because the hospital has been shut down for weeks as its parent company, Prospect Medical Holdings, deals with bankruptcy.
CBS Philadelphia
VMSC Emergency Medical Services, whose staff members were on scene, took Shyanne by ambulance to Nemours Children's Hospital in Wilmington, a 20-minute drive away, where she was given a diagnosis.
"They said it was an episode called BRUE, where it's like a brief resolved unexplained episode where babies will stop breathing for a brief moment," Whitaker said.
Whitaker fears what could have happened if paramedics hadn't been in the right place at the right time.
"It's fortunate that she [my daughter] was okay, but not everyone is going to have the same, you know, outcome," Whitaker said. "Thank you to the paramedics, to the cop who helped do the baby Heimlich, who got her to breathe again."
Whitaker said her scare speaks to the potential consequences of a growing healthcare desert in Delaware County.
"I couldn't imagine if something would have happened to my sister's only child, my only niece," Dickerson.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
a day ago
- Fox News
HHS revives child vaccine task force
Pediatrician Dr. Dyan Hes discusses the latest efforts by NIH to promote child vaccine safety and the 'carnivore babies' diet trend taking off online.
Yahoo
3 days ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025
Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires additional time to compile certain information, including recent developments, into the Form 10-Q necessary for a complete presentation, which it is unable to complete without unreasonable effort. A live webcast of the conference call will be available on the Company's website at Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865. About NRx Pharmaceuticals, Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Brian Korb Co-CEO, Hope Therapeutics, Inc. Managing Partner, astr Partners Chief Business Officer, NRx Pharmaceuticals, Inc. (917) 653-5122 mduffy@ View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Wegmans recalls cheese products due to potential listeria contamination
Wegmans is recalling its brand of medium camembert cheese and products that contain it due to potential listeria contamination, which can lead to serious illness. In an alert Wednesday, the U.S. Food and Drug Administration said the affected items, which were sold between July 1 and Aug. 12, include: Wegmans Medium Camembert Soft Ripened Cheese, 8.8 OZ — UPC: 77890-53515 with best by dates of 7/26/25, 8/12/25, and 8/19/ Assorted Cheese Flight, 1 LB — UPC: 2-77100-00000-0. Wegmans Grilling Camembert with Tapenade & Roasted Tomatoes, 10 OZ — UPC: 2-77297-00000-0. Wegmans Caramel Apple Pecan Topped Brie Cheese, 13 OZ — UPC: 2-77645-00000-3. The affected products were sold at Wegmans in the following locations: ConnecticutDelawareMarylandMassachusettsNew JerseyNew YorkNorth CarolinaPennsylvaniaVirginiaWashington, D.C. So far, no illnesses have been reported to Wegmans or its supplier, but officials say customers should not consume the products and can return them for a full refund. Listeria infections are caused by eating food contaminated with the bacteria called Listeria monocytogenes. In healthy individuals, short-term symptoms may include high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. But for young children, the elderly and those with weakened immune systems, the infection can be serious and sometimes fatal. Listeria infection can also cause miscarriages and stillbirths in pregnant women. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Could Tropical Storm Erin become the first Atlantic hurricane of 2025? Trump claims "land swapping" between Russia, Ukraine will happen Solve the daily Crossword
